Convened IRB: Operational Review Policy/Procedure

Internal Approval
SVP, Research
EVP & Chief Scientific Officer, Research

Scope
This policy describes the conduct of Institutional Review Board (IRB) procedures as it pertains to protocols, continuing review, amendments/revisions, and adverse events/unanticipated problems that involve risk to subjects that undergo full committee review by the convened IRB.

Policy Statements
Boston Children's Hospital has established and maintains an Institutional Review Board (IRB). The IRB's primary responsibility is the protection of research subjects.

The IRB reviews research protocols for issues in design and conduct that may potentially affect the safety, rights, and welfare of human subjects. The review procedures comply with federal regulations, state laws, and institutional polices. The IRB has established procedures to ensure a consistent review process for all initial reviews, continuing reviews/administrative updates, amendments/revisions, and unanticipated problems that involve risk to subjects or others.

The convened IRB meets, at a minimum, on the second and fourth Monday of each month. More frequent meetings may be held as required. IRB members are provided protocol materials five to seven days prior to the meeting.
Procedures

Administrative Pre-Review

The IRB administrative staff will review all protocols for completeness and consistency. They will provide the investigator with feedback, questions, and/or concerns.

1. Prior to the convened IRB meeting, IRB administrative staff will provide advice as to what will likely be acceptable within IRB policies and provide feedback on the protocol.
2. Before protocols are placed on the IRB meeting agenda, the investigator must respond to the issues raised and changes requested through the pre-review process.

Agenda

After the pre-review process, protocols are placed on the agenda in the order in which they are received, a “first come, first serve” basis.

1. If an agenda is full, the protocol will be placed on the next open meeting agenda.
2. Deferrals are always placed in the agenda for the next upcoming meeting regardless of the number of new protocols received.

Quorum and Representation

Quorum

For the convened IRB to hold a meeting at which actions can be taken, a quorum of members must be present.

1. A quorum consists of more than half of the IRB members.
2. If a quorum is lost during a meeting, no further actions will be taken.

Representation

IRB Member representation is important. One member may serve more than one role. Represented roles should include:

1. A scientific member
2. At least one member whose primary concerns are non-scientific
3. One member who is not affiliated with the hospital
4. One member who represents the general perspective of subjects.
5. A physician member must be present during the review of any clinical research study that involves the use of a Food and Drug Administration-regulated drug, device, or biologic.

Voting Actions and Documentation

Voting Actions
Approval: When an acceptable risk/benefit ratio exists, and the protocol is approved as submitted.

1. For research to be approved, it requires the approval of the majority of those members present at the meeting.

Conditional Approval: When the IRB reviews and approves a research study (or proposed changes to a previously approved research study), the IRB requires as a condition of approval that the investigator:

1. Make specified changes to the research protocol or informed consent document(s),
2. Confirm specific assumptions or understandings on the part of the IRB regarding how the research will be conducted, or
3. Submit additional documents, such that, based on the assumption that the conditions are satisfied, the IRB is able to make all of the determinations required for approval under the federal regulations.

When the IRB members determine a protocol is conditionally approved, they also must decide if:

1. the response is sent back to the IRB member primary and secondary reviewers or
2. the IRB analysts (who are also IRB members) to confirm all changes and requests have been made.

Deferral: When the changes proposed, or questions raised by the IRB prevent the IRB from making one or more of the determinations and specific changes required for approval by the regulations. Due to:

1. Lack of information or concerns raised in terms of risks and benefits
2. Adequacy of privacy and confidentiality protections
3. Adequacy of the informed consent process

Examples of reasons for deferral include:

1. The protocol was poorly written, lacking significant amounts of information regarding scientific justification, procedures, and/or risk reduction.
2. There are significant ethical concerns that do not permit a favorable risk/benefit determination.
3. More information is required or changes in design and procedures must be implemented.
4. There are clarifications and modifications requested directly relevant to determinations required by the regulations such as the data and safety monitoring plan.

All responses to deferrals are placed back before the convened IRB for review.

Disapproval: When after consultation with the investigator, the IRB determines that the research presents subject risks far outweigh the benefit or value of the knowledge to be gained; or the research raises such serious ethical questions as to be unacceptable. In the event disapproval is foreseen, the investigator is invited to attend the meeting to discuss the protocol.

Voting Documentation

1. At the convened IRB meeting, a vote is taken and recorded.
2. The total number of votes is always equal to the total number of members present at the meeting.

3. Minority Reporting: Those members who vote against a majority action on a research protocol is encouraged and is noted within the minutes.

**Conflict of Interest (COI)**

IRB members must not be involved in the review of any protocol in the conduct of the research protocol or have any other conflict of interest.

1. IRB members are expected to inform the IRB if they have a conflict prior to the discussion of any item on the agenda.
   a. In addition, the reviewer worksheets ask IRB members to indicate that they have no COI

2. Any IRB member who has a COI (i.e. is involved in the protocol or has other conflicts) may be asked questions about the content of the protocol, but cannot be present beyond the discussion of questions and answers, and cannot be present during the final discussion and vote.

3. If it is not obvious that an IRB member is involved in a protocol (i.e. is not listed as a participating investigator), and the protocol is assigned to that member, it is that member’s responsibility to inform the IRB administrative office. The IRB member will be expected to relinquish responsibility for reviewing the protocol.

**Primary & Secondary Reviewers**

All new protocols are assigned a primary and a secondary reviewer. The primary and secondary reviewers are responsible for a complete review and summary of the protocol application.

1. Expertise: At least one of the two reviewers must have the appropriate expertise to review the topic of the protocol. If there is not appropriate expertise:
   a. either an outside consultant will be sought, or
   b. the protocol will be rescheduled for review when expertise is obtained.

2. Convened IRB presentation: The primary and secondary reviewers present the protocol to the IRB at a convened meeting.
   a. The primary reviewer presents a brief summary of the protocol, followed by their comments.
   b. The secondary reviewer presents their comments only.
   c. Following presentation by the primary and secondary reviewer, the IRB is invited to provide additional comments.
      i. All members are asked to review all protocols and informed consents in preparation for the discussion.

3. Primary and secondary reviewers receive a Reviewer Worksheet that must be completed and uploaded in IRB electronic system prior to IRB meeting.
a. The use of this worksheet is mandatory.
b. The worksheet guides the reviewer comments and is structured to discuss the
issues within the context of the regulatory criteria.
c. The worksheet requires that reviewers consider all the regulatory criteria required for
approval.

Full IRB Committee Discussion
Following the full discussion of the convened IRB, the primary and secondary reviewers will suggest a
voting action to be taken.

1. The IRB Chair calls for a committee vote.
2. In general, the Chair will continue discussion until it appears that consensus is reached but a
vote may be called at any time.

Initial Reviews of New Protocols
New research protocol applications that do not meet the criteria for exemption or expedited review are
placed on the agenda for convened IRB review. Protocols are discussed on an individual basis.

1. All protocols are submitted electronically and made available to IRB members through the
CHeRP system.
   a. All IRB members have full access to the complete submission under review.
   b. The electronic submission utilizes a series of SmartForms that request specific
      information for all protocols (e.g. research team, financial disclosure, funding
      information) and then branch to other forms as necessary for the category of
      research under consideration.
      i. Document uploads are in multiple sections of the SmartForms where the
         research team can provide complete information required for IRB review.

Amendments/Revisions
All revisions/amendments that do not meet the criteria for expedited review are placed on the agenda for
the convened IRB meeting. All members are provided with a copy of the amendment/revision request
form with the proposed changes listed along with the rationale for the change.

1. Each amendment is assigned a primary and a secondary reviewer.
   a. Reviewers get a Reviewer Worksheet that needs to be completed and submitted at
      the end of the meeting.

2. The CHeRP system allows members to review side-by-side the sections of the SmartForm and
   attached materials that have been changed.
   a. Revised consents and recruitment notices are submitted in tracked changes to
      improve efficiency and effectiveness of the review process.

3. The voting procedures listed above apply to the review and voting process for amendments/
Continuing Reviews

Continuing reviews that meet the regulatory criteria for expedited review are not placed on the agenda for full IRB review.

1. Each continuing review is assigned a primary reviewer.
   a. A Reviewer Worksheet is provided and needs to be completed and submitted at the end of the meeting. The worksheet is structured so that the reviewer can determine whether the regulatory criteria continue to be met.

2. Through the CHeRP system, the primary reviewer is provided with a copy of the continuing review SmartForm. They also have access to the entire protocol, and associated materials, including study history (i.e. previous continuing reviews and Reportable Events).

3. The procedures listed above apply to the review and voting process for continuing reviews.

4. The IRB determines the time frame for the subsequent continuing review.
   a. The continuing review time period must be set to occur within 1 year of the approval date.
   b. The default is one year, unless the IRB votes otherwise.

Protocols that require continuing review in accordance with the Revised Common Rule, effective January 19, 2019 and the protocols approved prior to that date are referenced in the IRB policy: Continuing Review and Administrative Updates.

Unanticipated Events (UAP)

Unanticipated events that have been reviewed by the IRB chair and determined to require the full IRB's review are placed on the convened IRB meeting agenda.

1. Each UAP is assigned a primary reviewer.

2. The reviewer will present the event, corrective actions, and provide comments as necessary.

3. Through the CHeRP system, the reviewer has access to the entire protocol file, including previous reportable events.

4. The IRB voting actions are to:
   a. Accept the event
   b. Request additional information or
   c. Suspend recruitment or the entire protocol as necessary.

5. The IRB will also vote as to whether the event meets the criteria for reporting.

Reports of Action Procedures

A written report of action is prepared by the IRB administrative staff for all actions mentioned above.
1. The Senior Director of Clinical Research Compliance or Director are responsible for the final review of all reports of action before they are sent to principal investigators.

2. The IRB Chair and any IRB member may ask to review a draft of the report of action for any protocol, continuing review, or amendment/modification before it is sent to the investigator.

3. As necessary, the Senior Director of Clinical Research Compliance, Director, and the IRB administrative staff may ask IRB Chair or members to review reports of action prior to sending them to the investigator.

4. Whenever possible, reports of action are forwarded to investigators within seven days of the convened IRB meeting.

5. Copies of all reports of action included in the CHeRP protocol file.

Related Content

- IRB Policies
  - Amendments and Revisions
  - Continuing Review and Administrative Updates
  - Disapprovals and Appeals (For more information on research protocols that have been disapproved by the IRB)
  - Institutional Review Board Conflict of Interest (For more information concerning COI and IRB members)
  - Convened IRB Meeting Minutes (For more information on voting during the convened IRB meeting)
  - For more information concerning criteria for reporting:
    - Noncompliance: Investigations and Determinations
    - Reporting
    - Suspensions, Terminations, Administrative Closures, Investigator-Initiated Voluntary Suspension or Termination
    - Unanticipated Problems Involving Risks to Research Subjects and Others Including Adverse Events

- IRB Forms
  - Reviewer Worksheets:
    - Initial Review
    - Amendments
    - Continuing Reviews

Approval Signatures